Loading…
Cost of Illness in Inflammatory Bowel Disease
Background Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown. Aim To evaluate the annual costs for treati...
Saved in:
| Published in: | Digestive diseases and sciences 2017-09, Vol.62 (9), p.2318-2326 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c439t-76e108ad8cc732f9f4c0148439e8b454b427f67d0d588d5af1b036c696937ea63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c439t-76e108ad8cc732f9f4c0148439e8b454b427f67d0d588d5af1b036c696937ea63 |
| container_end_page | 2326 |
| container_issue | 9 |
| container_start_page | 2318 |
| container_title | Digestive diseases and sciences |
| container_volume | 62 |
| creator | Kamat, Nagesh Ganesh Pai, C. Surulivel Rajan, M. Kamath, Asha |
| description | Background
Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown.
Aim
To evaluate the annual costs for treating Crohn’s disease and ulcerative colitis.
Methods
A prevalence-based, micro-costing method was used to assess the components of annual costs in a prospective, observational study conducted in a tertiary healthcare center enrolled over a 24-month period beginning of July 2014.
Results
At enrollment, 43/59 (72.88%) patients with UC and 18/25 (72%) with CD were in remission. The annual median (IQR) cost per UC and CD patient in remission was INR 43,140 (34,357–51,031) [USD $707 (563–836)] and INR 43,763.5 (32,202–57,372) [USD $717 (527–940)], respectively, and in active disease was INR 52,436.5 (49,229–67,567.75) [$859 (807–1107)] and INR 72,145 (49,447–92,212) [USD $1182 (811–1512)], respectively. Compared with remission, active disease had a 1.4-fold higher cost for CD as compared to UC. In both groups, the greatest component of direct costs was drugs. Thirteen (22%) and 7 (28%) patients with UC and CD needed hospitalization accounting for 23.1 and 20.4% of the total costs, respectively. At one year, direct costs surmounted indirect costs in UC and CD (
p
|
| doi_str_mv | 10.1007/s10620-017-4690-z |
| format | article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1925514468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A712938004</galeid><sourcerecordid>A712938004</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-76e108ad8cc732f9f4c0148439e8b454b427f67d0d588d5af1b036c696937ea63</originalsourceid><addsrcrecordid>eNp1kU9v1DAQxa0KRLctH6CXKhIXLikzjuM_x3ahsFIlLvRseZ1xlSqJi51V1X56HG2BgkBz8Gjm957GeoydIpwjgPqQESSHGlDVQhqonw7YClvV1LyV-hVbAcrSI8pDdpTzHQAYhfINO-RaSclFs2L1Oua5iqHaDMNEOVf9VG2mMLhxdHNMj9VlfKCh-thncplO2Ovghkxvn99jdnP16dv6S3399fNmfXFde9GYuVaSELTrtPeq4cEE4QGFLjvSW9GKreAqSNVB12rdtS7gFhrppZGmUeRkc8ze733vU_y-ozzbsc-ehsFNFHfZouFti0JIXdB3f6F3cZemct1CGQHFUvymbt1Atp9CnJPzi6m9UMhNowEW6vwfVKmOxt7HiUJf5n8IcC_wKeacKNj71I8uPVoEu0Rk9xHZEpFdIrJPRXP2fPBuO1L3S_EzkwLwPZDLarql9OJH_3X9AejVl5Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1929409374</pqid></control><display><type>article</type><title>Cost of Illness in Inflammatory Bowel Disease</title><source>Springer Link</source><creator>Kamat, Nagesh ; Ganesh Pai, C. ; Surulivel Rajan, M. ; Kamath, Asha</creator><creatorcontrib>Kamat, Nagesh ; Ganesh Pai, C. ; Surulivel Rajan, M. ; Kamath, Asha</creatorcontrib><description>Background
Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown.
Aim
To evaluate the annual costs for treating Crohn’s disease and ulcerative colitis.
Methods
A prevalence-based, micro-costing method was used to assess the components of annual costs in a prospective, observational study conducted in a tertiary healthcare center enrolled over a 24-month period beginning of July 2014.
Results
At enrollment, 43/59 (72.88%) patients with UC and 18/25 (72%) with CD were in remission. The annual median (IQR) cost per UC and CD patient in remission was INR 43,140 (34,357–51,031) [USD $707 (563–836)] and INR 43,763.5 (32,202–57,372) [USD $717 (527–940)], respectively, and in active disease was INR 52,436.5 (49,229–67,567.75) [$859 (807–1107)] and INR 72,145 (49,447–92,212) [USD $1182 (811–1512)], respectively. Compared with remission, active disease had a 1.4-fold higher cost for CD as compared to UC. In both groups, the greatest component of direct costs was drugs. Thirteen (22%) and 7 (28%) patients with UC and CD needed hospitalization accounting for 23.1 and 20.4% of the total costs, respectively. At one year, direct costs surmounted indirect costs in UC and CD (
p
< 0.001). Productivity losses contributed to 18.5 and 16% of the overall costs for UC and CD, respectively.
Conclusion
This first, panoptic, health economic study for IBD from India shows that the costs are driven by medication, productivity losses, and not merely hospitalization alone.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-017-4690-z</identifier><identifier>PMID: 28766243</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adolescent ; Adult ; Aged ; Biochemistry ; Colon ; Cost of Illness ; Crohn's disease ; Economic aspects ; Female ; Follow-Up Studies ; Gastroenterology ; Hepatology ; Hospitalization ; Humans ; India - epidemiology ; Inflammatory bowel disease ; Inflammatory Bowel Diseases - economics ; Inflammatory Bowel Diseases - epidemiology ; Inflammatory Bowel Diseases - therapy ; Male ; Medical care, Cost of ; Medicine ; Medicine & Public Health ; Middle Aged ; Oncology ; Original Article ; Prospective Studies ; Transplant Surgery ; Ulcerative colitis ; Young Adult</subject><ispartof>Digestive diseases and sciences, 2017-09, Vol.62 (9), p.2318-2326</ispartof><rights>Springer Science+Business Media, LLC 2017</rights><rights>COPYRIGHT 2017 Springer</rights><rights>Digestive Diseases and Sciences is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-76e108ad8cc732f9f4c0148439e8b454b427f67d0d588d5af1b036c696937ea63</citedby><cites>FETCH-LOGICAL-c439t-76e108ad8cc732f9f4c0148439e8b454b427f67d0d588d5af1b036c696937ea63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28766243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kamat, Nagesh</creatorcontrib><creatorcontrib>Ganesh Pai, C.</creatorcontrib><creatorcontrib>Surulivel Rajan, M.</creatorcontrib><creatorcontrib>Kamath, Asha</creatorcontrib><title>Cost of Illness in Inflammatory Bowel Disease</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><addtitle>Dig Dis Sci</addtitle><description>Background
Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown.
Aim
To evaluate the annual costs for treating Crohn’s disease and ulcerative colitis.
Methods
A prevalence-based, micro-costing method was used to assess the components of annual costs in a prospective, observational study conducted in a tertiary healthcare center enrolled over a 24-month period beginning of July 2014.
Results
At enrollment, 43/59 (72.88%) patients with UC and 18/25 (72%) with CD were in remission. The annual median (IQR) cost per UC and CD patient in remission was INR 43,140 (34,357–51,031) [USD $707 (563–836)] and INR 43,763.5 (32,202–57,372) [USD $717 (527–940)], respectively, and in active disease was INR 52,436.5 (49,229–67,567.75) [$859 (807–1107)] and INR 72,145 (49,447–92,212) [USD $1182 (811–1512)], respectively. Compared with remission, active disease had a 1.4-fold higher cost for CD as compared to UC. In both groups, the greatest component of direct costs was drugs. Thirteen (22%) and 7 (28%) patients with UC and CD needed hospitalization accounting for 23.1 and 20.4% of the total costs, respectively. At one year, direct costs surmounted indirect costs in UC and CD (
p
< 0.001). Productivity losses contributed to 18.5 and 16% of the overall costs for UC and CD, respectively.
Conclusion
This first, panoptic, health economic study for IBD from India shows that the costs are driven by medication, productivity losses, and not merely hospitalization alone.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Biochemistry</subject><subject>Colon</subject><subject>Cost of Illness</subject><subject>Crohn's disease</subject><subject>Economic aspects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gastroenterology</subject><subject>Hepatology</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>India - epidemiology</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory Bowel Diseases - economics</subject><subject>Inflammatory Bowel Diseases - epidemiology</subject><subject>Inflammatory Bowel Diseases - therapy</subject><subject>Male</subject><subject>Medical care, Cost of</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>Original Article</subject><subject>Prospective Studies</subject><subject>Transplant Surgery</subject><subject>Ulcerative colitis</subject><subject>Young Adult</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp1kU9v1DAQxa0KRLctH6CXKhIXLikzjuM_x3ahsFIlLvRseZ1xlSqJi51V1X56HG2BgkBz8Gjm957GeoydIpwjgPqQESSHGlDVQhqonw7YClvV1LyV-hVbAcrSI8pDdpTzHQAYhfINO-RaSclFs2L1Oua5iqHaDMNEOVf9VG2mMLhxdHNMj9VlfKCh-thncplO2Ovghkxvn99jdnP16dv6S3399fNmfXFde9GYuVaSELTrtPeq4cEE4QGFLjvSW9GKreAqSNVB12rdtS7gFhrppZGmUeRkc8ze733vU_y-ozzbsc-ehsFNFHfZouFti0JIXdB3f6F3cZemct1CGQHFUvymbt1Atp9CnJPzi6m9UMhNowEW6vwfVKmOxt7HiUJf5n8IcC_wKeacKNj71I8uPVoEu0Rk9xHZEpFdIrJPRXP2fPBuO1L3S_EzkwLwPZDLarql9OJH_3X9AejVl5Q</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Kamat, Nagesh</creator><creator>Ganesh Pai, C.</creator><creator>Surulivel Rajan, M.</creator><creator>Kamath, Asha</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20170901</creationdate><title>Cost of Illness in Inflammatory Bowel Disease</title><author>Kamat, Nagesh ; Ganesh Pai, C. ; Surulivel Rajan, M. ; Kamath, Asha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-76e108ad8cc732f9f4c0148439e8b454b427f67d0d588d5af1b036c696937ea63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Biochemistry</topic><topic>Colon</topic><topic>Cost of Illness</topic><topic>Crohn's disease</topic><topic>Economic aspects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gastroenterology</topic><topic>Hepatology</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>India - epidemiology</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory Bowel Diseases - economics</topic><topic>Inflammatory Bowel Diseases - epidemiology</topic><topic>Inflammatory Bowel Diseases - therapy</topic><topic>Male</topic><topic>Medical care, Cost of</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>Original Article</topic><topic>Prospective Studies</topic><topic>Transplant Surgery</topic><topic>Ulcerative colitis</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kamat, Nagesh</creatorcontrib><creatorcontrib>Ganesh Pai, C.</creatorcontrib><creatorcontrib>Surulivel Rajan, M.</creatorcontrib><creatorcontrib>Kamath, Asha</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>ProQuest_Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kamat, Nagesh</au><au>Ganesh Pai, C.</au><au>Surulivel Rajan, M.</au><au>Kamath, Asha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost of Illness in Inflammatory Bowel Disease</atitle><jtitle>Digestive diseases and sciences</jtitle><stitle>Dig Dis Sci</stitle><addtitle>Dig Dis Sci</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>62</volume><issue>9</issue><spage>2318</spage><epage>2326</epage><pages>2318-2326</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><abstract>Background
Frequent relapses sometimes necessitating hospitalization and the absence of pharmacological cure contribute to substantial healthcare costs in inflammatory bowel diseases (IBDs). The costs of health care in Indian patients with IBD are unknown.
Aim
To evaluate the annual costs for treating Crohn’s disease and ulcerative colitis.
Methods
A prevalence-based, micro-costing method was used to assess the components of annual costs in a prospective, observational study conducted in a tertiary healthcare center enrolled over a 24-month period beginning of July 2014.
Results
At enrollment, 43/59 (72.88%) patients with UC and 18/25 (72%) with CD were in remission. The annual median (IQR) cost per UC and CD patient in remission was INR 43,140 (34,357–51,031) [USD $707 (563–836)] and INR 43,763.5 (32,202–57,372) [USD $717 (527–940)], respectively, and in active disease was INR 52,436.5 (49,229–67,567.75) [$859 (807–1107)] and INR 72,145 (49,447–92,212) [USD $1182 (811–1512)], respectively. Compared with remission, active disease had a 1.4-fold higher cost for CD as compared to UC. In both groups, the greatest component of direct costs was drugs. Thirteen (22%) and 7 (28%) patients with UC and CD needed hospitalization accounting for 23.1 and 20.4% of the total costs, respectively. At one year, direct costs surmounted indirect costs in UC and CD (
p
< 0.001). Productivity losses contributed to 18.5 and 16% of the overall costs for UC and CD, respectively.
Conclusion
This first, panoptic, health economic study for IBD from India shows that the costs are driven by medication, productivity losses, and not merely hospitalization alone.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28766243</pmid><doi>10.1007/s10620-017-4690-z</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2017-09, Vol.62 (9), p.2318-2326 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1925514468 |
| source | Springer Link |
| subjects | Adolescent Adult Aged Biochemistry Colon Cost of Illness Crohn's disease Economic aspects Female Follow-Up Studies Gastroenterology Hepatology Hospitalization Humans India - epidemiology Inflammatory bowel disease Inflammatory Bowel Diseases - economics Inflammatory Bowel Diseases - epidemiology Inflammatory Bowel Diseases - therapy Male Medical care, Cost of Medicine Medicine & Public Health Middle Aged Oncology Original Article Prospective Studies Transplant Surgery Ulcerative colitis Young Adult |
| title | Cost of Illness in Inflammatory Bowel Disease |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T13%3A18%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost%20of%20Illness%20in%20Inflammatory%20Bowel%20Disease&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=Kamat,%20Nagesh&rft.date=2017-09-01&rft.volume=62&rft.issue=9&rft.spage=2318&rft.epage=2326&rft.pages=2318-2326&rft.issn=0163-2116&rft.eissn=1573-2568&rft_id=info:doi/10.1007/s10620-017-4690-z&rft_dat=%3Cgale_proqu%3EA712938004%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-76e108ad8cc732f9f4c0148439e8b454b427f67d0d588d5af1b036c696937ea63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1929409374&rft_id=info:pmid/28766243&rft_galeid=A712938004&rfr_iscdi=true |